Literature DB >> 11940048

Poor uterine development in Turner syndrome with oral oestrogen therapy.

Wendy F Paterson1, Anne S Hollman, Malcolm D C Donaldson.   

Abstract

OBJECTIVE: To evaluate uterine development in Turner syndrome (TS) patients in relation to treatment with oral ethinyl oestradiol (E2 ) for pubertal induction. DESIGN AND PATIENTS: Pelvic ultrasound data for 96 TS patients scanned since 1989 were analysed. Patients were classified into three groups: (1) untreated (n = 48); (2) complete spontaneous puberty (n = 10); and (3) treated with ethinyl oestradiol (n = 38). Uterine development was described in the three groups and compared with the normal data. MEASUREMENTS: Uterine length, fundal-cervical ratio (FCR) and shape were recorded, and presence or absence of ovaries noted. In the treated group, cross-sectional and longitudinal data were combined to compare uterine development with Tanner breast stage.
RESULTS: In untreated girls up to age 10 years there was a variable distribution of uterine length and FCR about the mean. Thereafter, the uterus failed to grow and mature normally. Girls with complete spontaneous puberty had morphologically normal ovaries and uteri, but of 7 girls who attained menarche, 3 subsequently developed secondary oligomenorrhoea or amenorrhoea. In the treated group, in general, breast development and uterine length progressed with increasing E2 dose. However, only 50% of girls with complete secondary sexual development had a mature heart-shaped uterine configuration.
CONCLUSIONS: Our current E2 treatment regimen for TS girls gives rise to satisfactory pubertal induction and maintenance, but failed to induce a fully mature uterus in half the cohort. In view of the high risk of miscarriage in TS in both spontaneous and assisted pregnancies, the effect of more physiological methods of E2 replacement on uterine development should be investigated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11940048     DOI: 10.1046/j.1365-2265.2002.01477.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  9 in total

Review 1.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 2.  New issues in the diagnosis and management of Turner syndrome.

Authors:  Carolyn A Bondy
Journal:  Rev Endocr Metab Disord       Date:  2005-12       Impact factor: 6.514

Review 3.  Optimising management in Turner syndrome: from infancy to adult transfer.

Authors:  M D C Donaldson; E J Gault; K W Tan; D B Dunger
Journal:  Arch Dis Child       Date:  2006-06       Impact factor: 3.791

4.  Uterine development in Turner syndrome.

Authors:  Vladimir K Bakalov; Thomas Shawker; Irene Ceniceros; Carolyn A Bondy
Journal:  J Pediatr       Date:  2007-09-17       Impact factor: 4.406

Review 5.  The Care of Adolescents and Young Adults with Turner Syndrome: A Pediatric and Adolescent Gynecology Perspective.

Authors:  Tazim Dowlut-McElroy; Roopa Kanakatti Shankar
Journal:  J Pediatr Adolesc Gynecol       Date:  2022-03-08       Impact factor: 2.046

6.  Successful Pregnancy after Frozen Embryo Transfer after Recurrent Endometrial Collection in a Patient with Mosaic Turner Syndrome.

Authors:  Nidhi Goyal; K Jayakrishnan
Journal:  J Hum Reprod Sci       Date:  2021-03-30

7.  Menarche in primary ovarian insufficiency after a month of hormone replacement therapy: a case report.

Authors:  Biwen Cheng
Journal:  J Med Case Rep       Date:  2021-02-22

Review 8.  Early menopause: A hazard to a woman's health.

Authors:  Claudio Hernández-Angeles; Camil Castelo-Branco
Journal:  Indian J Med Res       Date:  2016-04       Impact factor: 2.375

9.  Uterine Development During Induced Puberty in Girls with Turner Syndrome.

Authors:  Monika Obara-Moszynska; Lukasz Dzialach; Barbara Rabska-Pietrzak; Marek Niedziela; Karina Kapczuk
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-06       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.